CA2484994C - Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes - Google Patents

Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Download PDF

Info

Publication number
CA2484994C
CA2484994C CA2484994A CA2484994A CA2484994C CA 2484994 C CA2484994 C CA 2484994C CA 2484994 A CA2484994 A CA 2484994A CA 2484994 A CA2484994 A CA 2484994A CA 2484994 C CA2484994 C CA 2484994C
Authority
CA
Canada
Prior art keywords
tgf
beta
seq
peptide
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2484994A
Other languages
English (en)
Other versions
CA2484994A1 (fr
Inventor
Jung San Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University filed Critical St Louis University
Publication of CA2484994A1 publication Critical patent/CA2484994A1/fr
Application granted granted Critical
Publication of CA2484994C publication Critical patent/CA2484994C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des procédés d'utilisation d'antagonistes peptidiques du TGF-bêta dans le but de faciliter la cicatrisation de plaies cutanées, notamment de brûlures, de lacérations et d'écorchures. L'administration à des plaies d'antagonistes peptidiques du TGF-bêta permet de réduire la formation de cicatrices, la contraction des plaies et le dépôt de composants matriciels extracellulaires, et elle permet également d'accroître les taux de ré-épithélialisation lors de la cicatrisation des plaies.
CA2484994A 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Expired - Lifetime CA2484994C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13594602A 2002-04-29 2002-04-29
US10/135,946 2002-04-29
PCT/US2003/011437 WO2003093293A2 (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Publications (2)

Publication Number Publication Date
CA2484994A1 CA2484994A1 (fr) 2003-11-13
CA2484994C true CA2484994C (fr) 2016-06-14

Family

ID=29399231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2484994A Expired - Lifetime CA2484994C (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Country Status (4)

Country Link
EP (1) EP1534737A4 (fr)
AU (1) AU2003234734A1 (fr)
CA (1) CA2484994C (fr)
WO (1) WO2003093293A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
CA2588292C (fr) * 2004-12-01 2019-01-15 Health Protection Agency Conjugues proteiques non cytotoxiques
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
KR20180029111A (ko) 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
CN102159219B (zh) 2008-09-16 2015-06-24 圣路易斯大学 提高转化生长因子-β信号发送的方法
CN102498128B (zh) * 2009-04-14 2015-02-18 凯尔格恩有限公司 具有转化生长因子的活性的肽及其用途
MX2012005340A (es) 2009-11-05 2012-12-05 Proyecto Biomedicina Cima Sl Sistemas de expresion regulada.
WO2012001196A2 (fr) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues
EP2407534A1 (fr) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Procédés et réactifs pour obtenir des particules virales actives du point de vue transcriptionnel et des virions recombinants
WO2013113755A1 (fr) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Réactifs et méthodes utilisables en vue du traitement de maladies par inhibition de la voie de signalisation calcineurine-nfat
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (fr) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Épisomes stables sur la base des vecteurs lentiviraux non intégratifs
WO2015101666A1 (fr) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia Vlp, procédés pour leur obtention et applications de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31

Also Published As

Publication number Publication date
AU2003234734A8 (en) 2003-11-17
CA2484994A1 (fr) 2003-11-13
WO2003093293A2 (fr) 2003-11-13
EP1534737A4 (fr) 2007-10-31
AU2003234734A1 (en) 2003-11-17
WO2003093293A3 (fr) 2005-04-07
EP1534737A2 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
CA2484994C (fr) Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes
US20110008248A1 (en) Peptide Antagonists of TGF-Beta Family Members and Therapeutic Uses Thereof
US6500431B1 (en) Inhibitors of angiogenesis and tumor growth
US5108989A (en) Method of predisposing mammals to accelerated tissue repair
EP0494264B1 (fr) Inhibition de facteur de croissance a transformation afin d'empecher l'accumulation de matrice extracellulaire
JP3054150B2 (ja) トロンビンから誘導されたポリペプチド、組成物およびその使用方法
US8691944B2 (en) Fibronectin polypeptides and methods of use
JPH08510443A (ja) 生物学的に活性なＴＧＦ−β１およびＴＧＦ−β２ペプチド
JPH0665680B2 (ja) 動物組織の修復
CA2859412C (fr) Distribution d'agents therapeutiques employant des segments polypeptidesliant un collagene bacterien
WO1995022979A1 (fr) Methode de traitement de certaines pathologies de l'oeil par des polypeptides
JPH07504650A (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
US6638912B2 (en) Peptide compositions mimicking TGF-β activity
US7772204B1 (en) Perlecan and growth factor for wound and cutaneous injury healing
JPH09505555A (ja) ＴＧＦ−βの活性を刺激および阻害する方法および組成物
US6500920B1 (en) Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
WO1999055861A2 (fr) Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
Huber et al. Activation of human platelet-derived latent transforming growth factor-β 1 by human glioblastoma cells. Comparison with proteolytic and glycosidic enzymes
ZA200104130B (en) Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof.
CA2106368A1 (fr) Methodes et compositions pour le traitement de la maladie angiogenique
US20100215583A1 (en) Cell nucleus-entering compositions
WO1998039436A2 (fr) Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions
WO1995015176A1 (fr) Procedes activant la duree de vie et facilitant la differentiation des sous-classes de neurones cholinergiques et serotonergiques a l'aide du facteur 5 de croissance des fibroblastes
AU2424599A (en) Recombinant proteins derived from hgf and msp

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230417